Krystal Biotech has built a franchise with wide moat characteristics — 54% net margins, a Rule of 40 score of 65, and a near-perfect Piotroski score of 9 out of 9 — and three consecutive earnings beats confirm the growth trajectory is intact; however, the stock has reached its near-term resistance target with effectively no remaining price headroom, and single-product concentration means any adverse development would impact the entire revenue base simultaneously.
Thesis pillars
- Wide Moat Elite Profitability→Stable
- Sustained Earnings Beat Streak↓Deteriorating
- Single Product Concentration↓Deteriorating
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Feb 17, 2026· older than 90 days
Krystal Biotech, Inc. (KRYS) Stock Analysis
Temporary headwind edge
Healthcare · Biotechnology
Wait for pullback to $287.81. Weak momentum; also insider activity concern — blocks BUY_NOW at $305.03. Engine's entry $287.81 (Default 5pct Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: VYJUVEK; Expensive valuation.
Krystal Biotech develops genetic medicines using an engineered HSV-1 platform, with VYJUVEK as its sole commercial product approved in the U.S. (2023), EU, and Japan (both 2025) for dystrophic epidermolysis bullosa. Since the 2023 U.S. launch, VYJUVEK has generated $730.3... Read more
Wait for pullback to $287.81. Weak momentum; also insider activity concern — blocks BUY_NOW at $305.03. Engine's entry $287.81 (Default 5pct Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: VYJUVEK; Expensive valuation. Chart setup: No clear chart pattern; technical signals are mixed. Growth is cheap relative to earnings, but the technical setup has not yet produced a breakout above resistance (PEG 1.38, quality 8.2/10, growth 8.4/10). Score 6.0/10, moderate confidence.
Passes 5/7 gates (favorable risk/reward ratio, no SEC red flags, earnings proximity 104d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: speculative.
About Krystal Biotech, Inc.
About Krystal Biotech, Inc.
VYJUVEK (beremagene geperpavec), the first-ever redosable gene therapy, generated $730.3 million in cumulative net product revenue since Krystal Biotech's U.S. launch in 2023 through fiscal year 2025. FDA approved VYJUVEK in May 2023 for dystrophic epidermolysis bullosa in patients six months and older; the European Commission granted marketing authorization in April 2025 and Japan's MHLW in July 2025, targeting an estimated 3,000 U.S. patients and over 9,000 worldwide. The company operates two in-house commercial-scale CGMP facilities in Pennsylvania.
Krystal Biotech commercializes VYJUVEK directly in the United States, major European markets, and Japan, and contracts with specialty distributors for territories including Central and Eastern Europe, the Middle East, Turkey, and Israel. Germany pricing negotiations are expected to continue through at least the second half of 2026; France pricing negotiations under the Accès Précoce program are expected to continue through 2027; and Italy launch discussions target the second half of 2026. Pipeline candidates include KB407, an inhaled gene therapy for cystic fibrosis in Phase 1 (CORAL-1), which reported positive Cohort 3 data in January 2026 and plans to initiate a potentially registrational CORAL-3 study in the first half of 2026; and KB408, targeting alpha-1 antitrypsin deficiency lung disease in Phase 1 (SERPENTINE-1), where a repeat-dose cohort was initiated in August 2025. The Inflation Reduction Act's Medicare drug-price negotiation provisions and subsequent executive orders directing additional drug pricing reforms add regulatory uncertainty to future VYJUVEK reimbursement conditions.
Show full overview
Krystal Biotech's financial performance rests on a single approved therapy: the 10-K states the company's near-term prospects and future growth are 'substantially dependent on the commercial success of VYJUVEK.' The BPCIA establishes a 12-year biologic exclusivity period from the May 2023 FDA approval, though competing biologics license applications may proceed independently during this window. The One Big Beautiful Bill Act, signed July 4, 2025, reduced Medicaid funding in ways that could affect patient access to high-cost gene therapies, adding a payer-access dimension to the single-product revenue risk.
See also: Healthcare · Biotechnology
From Krystal Biotech, Inc.'s most recent 10-K filing, extracted June 11, 2026.
Recent developments
updated Nov 4, 2026Recent Developments — Krystal Biotech, Inc.
Latest news
- NEWS Krystal Biotech (KRYS) Stock Jumps As Q3 Results Put Buyback First - Simply Wall St — Simply Wall St Nov 4, 2026 positive
- NEWS How Earnings Optimism At Krystal Biotech (KRYS) Has Changed Its Investment Story - Simply Wall St — Simply Wall St Oct 28, 2026 positive
- NEWS Krystal Biotech, Inc. Stock 12‑Month Price Target Raised to $409.38, Implies 28% Upside - TradingView — TradingView Oct 28, 2026 positive
- NEWS Krystal Biotech (KRYS) Could Be 17% Undervalued On Its Multiproduct Pipeline Story - Simply Wall Street — Simply Wall Street Oct 7, 2026 positive
- NEWS Why Krystal Biotech’s Hot Stock Is Suddenly Sinking - TipRanks — TipRanks Sep 23, 2026 negative
Latest item Nov 4, 2026 · Generated 2026-11-04T11:39:50Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductVYJUVEK10-K Item 1A: 'our near-term prospects...are substantially dependent on the commercial success of VYJUVEK'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $287.81. Weak momentum; also insider activity concern — blocks BUY_NOW at $305.03. Engine's entry $287.81 (Default 5pct Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: VYJUVEK; Expensive valuation. Chart setup: No clear chart pattern; technical signals are mixed. Growth is cheap relative to earnings, but the technical setup has not yet produced a breakout above resistance (PEG 1.38, quality 8.2/10, growth 8.4/10). Target $342.39 (+12.2%), stop $272.96 (−11.7%), A.R:R 1.5:1. Score 6.0/10, moderate confidence.
Take-profit target: $342.39 (+12.2% upside). Target $342.39 (+12.2%), stop $272.96 (−11.7%), A.R:R 1.5:1. Stop-loss: $272.96.
Concentration risk — Product: VYJUVEK; Expensive valuation; Negative momentum.
Krystal Biotech, Inc. trades at a P/E of 41.4 (forward 33.4). TrendMatrix value score: 3.3/10. Verdict: Buy (Wait for Entry).
20 analysts rate KRYS, with a consensus score of 4.3/5. 9 analysts publish price targets averaging $394.
What does Krystal Biotech, Inc. do?Krystal Biotech develops genetic medicines using an engineered HSV-1 platform, with VYJUVEK as its sole commercial...
Krystal Biotech develops genetic medicines using an engineered HSV-1 platform, with VYJUVEK as its sole commercial product approved in the U.S. (2023), EU, and Japan (both 2025) for dystrophic epidermolysis bullosa. Since the 2023 U.S. launch, VYJUVEK has generated $730.3 million in cumulative net product revenue. Two in-house commercial-scale CGMP manufacturing facilities in Pennsylvania support worldwide supply.